1Blockchain in Healthcare Today ISSN 2573-8240 USE CASE Improving End-to-End Traceability and Pharma Supply Chain Resilience using Blockchain Corrine Sim ; Haisheng Zhang ; and Marianne Louise Chang Zuellig Pharma, Singapore Corresponding author: Marianne Louise Chang, Email: digicomms@zuelligpharma.com Keywords: blockchain, COVID-19, eZTracker, hyperledger fabric, pharma supply chain, traceability Abstract Regulating and monitoring a traditionally fragmented pharma supply chain has been a global challenge for decades. Without a trusted system and strong collaboration between stakeholders, threats such as counterfeits can easily intercept the supply chain and cause monumental disruptions. Today, the COVID-19 pandemic has accelerated the need for greater data transparency, better deployment of technology, and improved ways of connecting stakeholder information along the supply chain. There is a need for improved ways of working to help build up supply chain resilience, and one way is by implementing better end-to-end traceability using blockchain technology such as Hyperledger Fabric. This paper will explore the business value that blockchain brings to the pharma supply chain with better end-to-end traceability, using the example of an industry-grade blockchain solution called eZTracker. Through six key features, pharmaceutical manufacturers, patients, and Healthcare Practitioners (HCPs) can now participate in data sharing, with extended use cases of integrating blockchain with warehouse platforms, a patient-facing mobile application, and an interactive dashboard for real-time verification and data transpar- ency. Beyond anti-counterfeit verification, other potential use cases include effective product recall manage- ment, cold chain monitoring, e-product information, and more. The effectiveness of a traceability solution is heavily dependent on the amount of data collected and is affected by poor adoption and scalability. Existing limitations that need to be addressed include the lack of mandated serialization in Asia and blockchain interoperability. To maximize the value of blockchain, collaboration is the key. Pharmaceutical manufacturers need to invest in new technologies, such as blockchain, to help them break out of data silos and operationalize data to build supply chain resilience. Pharmaceutical supply chain is the backbone of a US$1.27 trillion industry,1 but because of its highly complex and fragmented nature, it is hard to regulate and protect, and this makes it a valuable target for opportunistic parties such as counterfeiters looking to profit.2 As a result of the COVID-19 pandemic, there has been greater emphasis on transparency of data and connect- ing stakeholders along the pharma supply chain in real-time in the last few years. With the introduction of blockchain technology, companies are now able to implement solutions with more effective track and trace results, providing quality assurance to pharmaceutical manufacturers, patients, and Healthcare Practitioners (HCPs), and even improving operational efficiencies. This paper seeks to explore the positive business impact of end-to-end traceability using blockchain technol- ogy, and the effects it brings about, such as improving supply chain resilience and combating counterfeits, as seen in successful live use cases in Asia. Received: April 28, 2022; Revised: July 20, 2022; Accepted: July 22, 2022; Published: August 12, 2022 Blockchain for End-To-End Traceability and Anti- Counterfeit Verification According to a report by the World Economic Forum, the top three advantages of blockchain adoption for pharmaceutical and healthcare ecosystems are full trace- ability, data immutability, and increased security.3 These benefits will prove useful to address the challenges of poor trust, data sharing, and visibility across the supply chain. https://orcid.org/0000-0002-0957-9202 https://orcid.org/0000-0002-4263-2183 mailto:digicomms@zuelligpharma.com Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.2312 Corrine Sim and Haisheng Zhang Blockchain is a distributed ledger technology that re- cords transaction data in a “block” and is linked to the preceding “block,” forming a long chain in chronological order4 (Figure 1). There are four types of blockchain networks: public, private, consortium, and hybrid.6 For enterprise applica- tions, private or consortium blockchains are preferred, as they are permissioned blockchains that promote high security by limiting access to only approved parties and implementing data access controls and privacy policies across the network.7 These are crucial in the healthcare and pharmaceutical ecosystem, which handles sensitive information such as patient health data and intellectual properties of manufacturers. Another benefit of permis- sioned blockchains is scalability because of the modular architecture. Methods Selecting a Blockchain Framework One of the existing blockchain frameworks, Hyperledger Fabric, is an open-source industry-grade framework hosted by The Linux Foundation. Designed for enterprise applications across industries, Hyperledger Fabric has au- tomatic executable smart contracts (or chain codes) that are business logic algorithms and are mutually agreed upon by all parties on the network. With each transac- tion, every party will endorse the transaction based on a sophisticated pre-set endorsement policy.8 Providing higher data security compared to traditional centralized solutions that may suffer from a single point of failure or attacks by malicious parties,9 Hyperledger Fabric passed a series of detailed security reviews and assessments in 2021 and was deemed “natively secure by both design and default” by the Cloud Security Alliance.10 Deploying Blockchain for Anti-Counterfeit Verification More than one in 10 drugs in developing countries are estimated to be counterfeited,11 with types of therapeutic categories being falsified growing annually.12 This has resulted in the pharma supply chain to suf- fer from eroding trust – a study revealed that seven in 10 patients were concerned about receiving harmful counterfeit or substandard products.13 In 2021, the Edel- man Trust Barometer reported that more than 50% of countries they surveyed reported decreasing trust in pharmaceutical companies compared to 2020.14 With an estimate of over 1 million deaths caused by counterfeit and substandard drugs annually, patients around the world are increasingly demanding to know the origin of their drugs.15 Hyperledger Fabric can be used in combination with tamper-proof serialization labels to allow more secure verification of product provenance in real-time. Counter- feiters who create a fraudulent identity or tamper with the data violate endorsement policy and the abnormal data transaction will alert all users in the ecosystem. A shared visible ledger can also help improve supply chain transparency16 by allowing HCPs and patients to access accurate product provenance data, verify product distribution channels, and report counterfeit incidents in real time. Fig. 1. How blocks are chained to form a blockchain.5 http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.231 3 Improving end-to-end traceability and pharma supply chain resilience Using blockchain, pharmaceutical manufacturers are now able to connect stakeholders along the pharma sup- ply chain for meaningful real-time interactions such as adverse-event reporting. In 2019, Hong Kong authorities discovered clinics were administering counterfeit Human Papilloma Virus (HPV) vaccines.17 This incident caused public panic and complaints among patients worried about the authentic- ity and safety of the vaccines. In the same year, 400,000 counterfeit beauty products were seized by Thailand’s Department of Special Investigations, including der- mal fillers.18 Consequences of injecting falsified fillers include risks of unevenness of the skin, cell death, and even blocked arteries that may lead to blindness.19 In response to the incidents, several pharmaceutical manufacturers deployed eZTracker, an end-to-end trace- ability solution using blockchain that allowed patients and HCPs to verify the authenticity of distribution while providing pharmaceutical manufacturers with dash- boards for real-time track and trace. Results and Discussion Real-Time Verification Solution For effective track and trace and to especially fight coun- terfeits, all stakeholders along the pharma supply chain need to be connected and break out of the traditional information silos. eZTracker is the first production-grade traceability solution that empowers pharmaceutical man- ufacturers, distributors, HCPs, and patients with real-time traceability (Figure 2). Pharmaceutical Manufacturers To enable track and trace, products are first serialized at a pack level. The encrypted Digital ID for each product is uploaded onto the blockchain as a new block and linked to new data transaction points, creating a string of trace- able and immutable historical data. By integrating warehouse operations systems with blockchain, pharmaceutical manufacturers can up- load existing key master product data through a simple Extract, Transform, and Load (ETL) system and tag se- lect information to each Digital ID. With this Application Programming Interface (API) integration, data can now be shared from various databases and made visible on the blockchain. For eZTracker, Digital IDs are encoded into 2D data matrixes on physical packs to allow them to be read by scanners across the supply chain (Figure 3). In 2022, eZ- Tracker was successfully used to record and track more than 2 million labeled products on the blockchain. Distributors Included in eZTracker Operations is the ZOIP app, a warehouse application that allows warehouse staff to scan 2D data matrix codes, tag products in the blockchain, and access key product information (Figure 4). The redressing team has the responsibility to use ZOIP to scan the newly affixed 2D data matrix to create unique box identities in the blockchain and tag the product to material and batch numbers. When the products are ready for dispatch, the picking team can seamlessly access pre- viously logged information and important dispatch infor- mation, including the invoice number, quantity ordered, client name, expiry date, and more (Figure 5). Healthcare Practitioners and Patients When dispatched products arrive at a clinic, hospital, or pharmacy, HCPs can validate the authenticity of the products received. Through eZTracker Connectors, built to connect and integrate healthcare management systems Fig. 2. Six eZTracker features to enable end-to-end traceability. Fig. 3. Printed encrypted 2D data matrix on product packaging. http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.2314 Corrine Sim and Haisheng Zhang to the blockchain, HCPs can now tag products in their inventory to specific activities such as from storage to administration. Each unique pack can also be tagged to individual patients, and this is especially important for pa- tient safety and quality assurance, such as in the case of product recalls where manufacturers and authorities can reach patients quickly and directly. Because of the array of use cases applicable with block- chain, eZTracker also launched a mobile app to empower HCPs and patients with the ability to verify the authentic- ity of product distribution in real-time. eZTracker is now used by more than 37,000 users in Hong Kong and Thai- land with over 115,000 scans, of which more than 6,700 scans indicated potential counterfeits and cross-border movement of products. Users can download the application from the Google Play Store or Apple App Store for free and scan the 2D data matrix on their products. If the mobile app verifies that the product comes from an authorized distribution source, users will be notified of key product information and its provenance (Figure 6). However, when an unauthorized product scan is de- tected, users will be alerted and prompted to report the incident with photographic evidence and a description. These reports will be sent to the pharmaceutical manu- facturers who can then use them for further investigations. Creating Insights from Blockchain Analytics for Counterfeit Detection With the launch of the integrated features and services, a robust and market-ready dashboard was built to oper- ationalize data shared across the blockchain (Figure 7). Supply chain data are fed into the dashboards every 15 min and insights accessed are close to real-time. These data are later exported easily for auditing and reporting purposes. This helps pharmaceutical manufacturers inves- tigate suspicious counterfeit activity and collect evidence to conduct investigations. With these analytics, pharmaceutical manufacturers are empowered with data to make decisions that affect risk management, brand integrity, security, and compliance. With a concerted and proactive effort to combat counter- feits, pharmaceutical manufacturers can now work closely with consumers to build a more secure ecosystem. There are currently three key components to the dashboard: Fig. 4. ZOIP warehouse application (scanning products). http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.231 5 Improving end-to-end traceability and pharma supply chain resilience (1) Product scan rates and dispatch information (Figure 8): product information is tracked to the indi- vidual pack level, and an unusually high frequency of scans could possibly indicate malicious parties looking to exploit vulnerabilities in the supply chain. (2) Authorized Scans versus Cross-border Scans (Figure 9): product scans on the mobile app are timestamped and uploaded into the blockchain. “Authorized” scans show products from an autho- rized source, whereas “Cross-border” scans could indicate products from unauthorized distributors, which could affect quality assurance and authentic- ity for the final user of the product. (3) Geolocation data (Figure 10): data of individual pack movements is collected when a product is scanned. Data can help to identify clusters of suspi- cious behavior and even the movement of these sus- picious goods, with the ability to zoom in on certain districts, neighborhoods, and specific coordinates. With blockchain-enabled end-to-end traceability, the data and reports submitted by consumers allow pharmaceutical manufacturers and local authorities to Fig. 5. eZTracker operations at a distributor’s warehouse. Fig. 6. eZTracker mobile app (verification flow). http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.2316 Corrine Sim and Haisheng Zhang Fig. 7. Blockchain integration with tableau. Fig. 8. Three individual product scan rates and dispatch information. Fig. 9. Comparison graph of “authorized” versus “cross-border” scans. http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.231 7 Improving end-to-end traceability and pharma supply chain resilience have a better understanding of potential counterfeit activities in the market and conduct more effective and data-driven counterfeit investigations. Other Benefits of End-to-End Traceability Timely Product Recalls Even as products are dispatched to clinics, hospitals, and pharmacies, each product’s digital ID can be tagged to key patient information, such as date of administration, contact details, product batch number, and more. This al- lows for more effective product recalls as manufacturers can engage patients directly instead of regular processes, which can take months or even years. Cold Chain Monitoring Temperature-sensitive products such as vaccines that are not kept at recommended storage requirements may lose their potency when exposed to heat.20 These damages re- sult in waste and can incur up to US$35 billion in losses annually for the pharmaceutical industry.21 When tem- perature data are collected in silos and not shared, it is difficult to detect products that are compromised. With blockchain, temperature data from loggers across the sup- ply chain can be added to the network to provide real-time temperature reports and more effective cold chain moni- toring. To improve efficiency even further, consumers can now verify for themselves whether the product was stored at approved temperatures through the mobile app and report any adverse events such as sub-standard storage of products. Electronic Product Information A product label is updated five times in a year on average, and pharma companies spend millions of dollars updat- ing artwork, printing, and working out the logistics for distributing updated labels.22 Paper package inserts and patient information leaflets do not give patients access to the latest approved information about the product. With ePI, manufacturers can manage their depository of prod- uct information online to produce consistent quality infor- mation. Instead of manual intervention, they can engage patients directly using the mobile app and trigger alerts and warnings in the event of product recalls and other up- dates in product information. Patients connected digitally can easily report adverse events. ePI is also cost-effective and reduces environmental impact. Improved Supply Chain Resilience End-to-end traceability improves supply chain visibil- ity and data-sharing access. Manufacturers can access actionable insights to develop effective strategies to op- timize their resources and tackle existing supply chain inefficiencies that free up net working capital. Positive working capital management reduces company risk and improves financial flexibility and performance, especially during a disruption such as the COVID-19 pandemic.23 Challenges to the Adoption of Blockchain in Pharma Supply Chain Lack of Mandated Product Serialization In Europe and the United States, drug serialization has been mandated since 2017 by the authorities, which helped facilitate the adoption of traceability solutions to improve transparency.24 However, in the ASEAN region, serialization is not widely practised, and this makes end- to-end traceability difficult to achieve uniformly across the region.25 Even with mandated serialization, reliable tracking technology is still necessary to enable effective product traceability. In a study, more than four in 10 pharmaceu- tical data management vendors exceeded a Ransomware Susceptibility Index (RSI) of 0.6, which meant that man- ufacturers were easily exposed to risks of data manipu- lation and disruption.26 Conventional data management architectures are not immune to vulnerabilities and may Fig. 10. Geolocation data and timelapse of scan history. http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.2318 Corrine Sim and Haisheng Zhang create distrust and impede data sharing across the supply chain. Data collection processes also need to evolve as poor quality of information impacts the success of traceabil- ity solutions.27 With different stages of the supply chain implementing non-standard processes to track products and enter varied data inputs, integration and data sharing require complex mapping, which is time-consuming and inefficient. Multi-Cloud Infrastructure and Future of Interoperability To enable end-to-end traceability, the blockchain must be agile enough for organizations to join seamlessly. In January 2022, eZTracker developed the first multi-cloud blockchain in the pharmaceutical industry. This means that client and partner nodes on any popular public cloud can integrate with eZTracker to connect and share data securely. With this cloud-agnostic architecture, automated node setups for partners and clients allow them to enjoy faster go-to-market times (Figure 11). However, as the solution scales, there is a risk of frag- mentation in the pharmaceutical supply chain if multi- ple blockchains exist independently, creating data and value silos.28 Blockchain interoperability helps enable scalability, reduce risk, and eliminate silos.29 The supply chain needs to prioritize blockchain interoperability to better scale traceability solutions, increase adoption, and potentially achieve global transparency through collaboration. Conclusion To better safeguard the pharmaceutical supply chain, adoption of blockchain for track and trace is the key for end-to-end traceability to improve patient safety and long-term supply chain resilience. Through its immutable, secure, and scalable network architecture, blockchain has shown to effectively build a culture of trust and collaboration to reduce data silos across the supply chain. Furthermore, this increased data transparency benefits pharmaceutical manufacturers, distributors, HCPs, and patients, as it unlocks the possibility of enabling real-time verification solutions for quality assurance and dash- boards that help unlock insightful data analytics. Blockchain adoption, scalability, and interoperabil- ity will remain critical criteria of success for end-to-end traceability solutions. The private and public sectors need to set a unified data-sharing standard, collaborate across Fig. 11. Multi-cloud blockchain architecture. http://dx.doi.org/10.30953/bhty.v5.231 Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.231 9 Improving end-to-end traceability and pharma supply chain resilience interoperable blockchain networks, and build trusted and connected data ecosystems. Funding Statement None Financial and Non-Financial Relationships and Activities None Authors’ contributions Corrine Sim and Marianne Chang wrote the paper. Haisheng Zhang contributed to the technical blockchain portions of the paper. References 1. Mikulic M. Topic: global pharmaceutical industry. Statista; 2021. Available from: https://www.statista.com/topics/1764/ global-pharmaceutical-industry/ [cited 18 December 2022]. 2. Bhosle MJ, Balkrishnan R. Drug reimportation practices in the United States. Ther Clin Risk Manag. 2007;3(1):41–6. https:// doi.org/10.2147/tcrm.2007.3.1.41 3. World Economic Forum. Building value with blockchain tech- nology: is blockchain worth the investment? World Economic Forum; 2019. Available from: https://www.accenture.com/_acn- media/pdf-105/accenture-blockchain-value-report.pdf [cited 28 April 2022]. 4. Crosby M, Pattanayak P, Verma S, Kalyanaraman V. Block- Chain technology beyond bitcoin. 2015. Available from: https:// scet.berkeley.edu/wp-content/uploads/BlockchainPaper.pdf [cited 28 April 2022]. 5. Agbo C, Mahmoud Q, Eklund J. Blockchain technology in healthcare: a systematic review. Healthcare. 2019;7(2):56. https:// doi.org/10.3390/healthcare7020056 6. Li Y. Emerging blockchain-based applications and techniques. Serv Orien Comput Appl. 2019;13(4):279–85. https://doi. org/10.1007/s11761-019-00281-x 7. Niemerg M. Private vs. public blockchains for enterprise busi- ness solutions. InfoQ; 2021. Available from: https://www.infoq. com/articles/enterprise-private-public-blockchains/ [cited 28 April 2022]. 8. Hyperledger. Architecture origins—hyperledger-fabricdocs master documentation. Hyperledger; 2019. Available from: https://hyperledger-fabric.readthedocs.io/en/release-1.4/arch- deep-dive.html [cited 28 April 2022]. 9. Elisa N, Yang L, Chao F, Cao Y. A framework of block- chain-based secure and privacy-preserving E-government system. Wirel Netw. 2018. https://doi.org/10.1007/s11276-018-1883-0 10. Cloud Security Alliance. New cloud security alliance research eval- uates Hyperledger Fabric 2.0 security, provides guidance mapped to NIST cybersecurity framework. Cloud Security Alliance; 2021. Avail- able from: https://cloudsecurityalliance.org/press-releases/2021/06/28/ new-cloud-security-alliance-research-evaluates-hyperledger-fab- ric-2-0-security-provides-guidance-mapped-to-nist-cybersecuri- ty-framework/ [cited 28 April 2022]. 11. World Health Organisation. 1 in 10 medical products in de- veloping countries is substandard or falsified. Who.int; 2017. Available from: https://www.who.int/news/item/28-11-2017-1-in- 10-medical-products-in-developing-countries-is-substandard- or-falsified [cited 28 April 2022]. 12. Pharmaceutical Security Institute. Therapeutic categories. Psi- inc.org; 2020. Available from: https://www.psi-inc.org/therapeu- tic-categories [cited 28 April 2022]. 13. Business Wire. Four-in-10 patients fear pharmaceutical sup- ply chain issues pose risk of illness, death. Businesswire.com; 2021. Available from: https://www.businesswire.com/news/ home/20211116005249/en/Four-in-10-Patients-Fear-Pharma- ceutical-Supply-Chain-Issues-Pose-Risk-of-Illness-Death [cited 28 April 2022]. 14. Edelman. Edelman Trust barometer 2021—Healthcare sector global. Edelman; 2021. Available from: https://www.edelman. com/sites/g/files/aatuss191/files/2021-05/Global Health Sector Barometer.pdf [cited 28 April 2022]. 15. World Health Organisation. Substandard and falsified medical products. Who.int; 2018. Available from: https://www.who.int/ news-room/fact-sheets/detail/substandard-and-falsified-medi- cal-products [cited 28 April 2022]. 16. Zelbst P, Green K, Sower V, Bond P. The impact of RFID, IIoT, and Blockchain technologies on supply chain transpar- ency. J Manuf Technol Manag. 2019;31(3):441–57. https://doi. org/10.1108/JMTM-03-2019-0118 17. Chiu P. Customs seize 76 boxes of suspected counterfeit HPV vaccines in Hong Kong after patient complains of redness and swelling at injected area. South Morning China Post; 2019. Available from: https://www.scmp.com/news/hong-kong/law- and-crime/article/3018443/customs-seize-76-boxes-suspect- ed-counterfeit-hpv [cited 28 April 2022]. 18. Thai Public Broadcasting Service. Officials seize Bt80m of fake Botox, stem cells and fillers in Bangkok. Thai PBS World; 2019. Available from: https://www.thaipbsworld.com/officials-seize- bt80m-of-fake-botox-stem-cells-and-fillers-in-bangkok/ [cited 28 April 2022]. 19. Liu K. Dermal fillers: The good, the bad and the dangerous. Harvard Health Publishing; 2019. Available from: https://www. health.harvard.edu/blog/dermal-fillers-the-good-the-bad-and- the-dangerous-201907152561 [cited 28 April 2022]. 20. World Health Organisation. Safe vaccine handling, cold chain and immunizations. 1998. Available from: https://apps.who.int/ iris/bitstream/handle/10665/64776/WHO_EPI_LHIS_98.02.pd- f?sequence=1&isAllowed=y [cited 28 April 2022]. 21. Pelican BioThermal. 2019 biopharma cold chain logis- tics survey. 2019. Available from: https://cdn2.hubspot.net/ hubfs/4107558/general content/PEL1046_SurveyReport_v4a. pdf ?__hssc=67202574.2.1584020853798&__hstc=67202574. a664b3 [cited 28 April 2022]. 22. Chaudhary P, Shetty V. E-labeling: change is underway. Phar- mExec; 2020. Available from: https://www.pharmexec.com/ view/e-labeling-change-underway [cited 29 April 2022]. 23. Achim MV, Safta IL, Văidean VL, Mureșan GM, Borlea NS. The im- pact of covid-19 on financial management: evidence from Romania. Economic Research-Ekonomska Istraživanja. 2022;35(1):1807–32. https://doi.org/10.1080/1331677X.2021.1922090 24. MarketsandMarkets Research Private Ltd. Track and Trace Solutions Market by Product (plant manager, checkweigher, barcode scanner, monitoring), technology (2D Barcode, RFID), application (serialization, aggregation, reporting), end user (pharma, food, medical devices) – Global Forecast to 2026. Marketsandmarkets; 2021. Available from: https://www.mar- ketsandmarkets.com/Market-Reports/track-trace-solution-mar- ket-158898570.html [cited 28 April 2022]. 25. Tongia Abhishek. The drug regulatory landscape in the ASEAN Region. Regulatory Affairs Professionals Society; 2018. Available from: https://www.raps.org/news-and-articles/ http://dx.doi.org/10.30953/bhty.v5.231 https://www.statista.com/topics/1764/global-pharmaceutical-industry/ https://www.statista.com/topics/1764/global-pharmaceutical-industry/ https://doi.org/10.2147/tcrm.2007.3.1.41 https://doi.org/10.2147/tcrm.2007.3.1.41 https://www.accenture.com/_acnmedia/pdf-105/accenture-blockchain-value-report.pdf https://www.accenture.com/_acnmedia/pdf-105/accenture-blockchain-value-report.pdf https://scet.berkeley.edu/wp-content/uploads/BlockchainPaper.pdf https://scet.berkeley.edu/wp-content/uploads/BlockchainPaper.pdf https://doi.org/10.3390/healthcare7020056 https://doi.org/10.3390/healthcare7020056 https://doi.org/10.1007/s11761-019-00281-x https://doi.org/10.1007/s11761-019-00281-x https://www.infoq.com/articles/enterprise-private-public-blockchains/ https://www.infoq.com/articles/enterprise-private-public-blockchains/ https://hyperledger-fabric.readthedocs.io/en/release-1.4/arch-deep-dive.html https://hyperledger-fabric.readthedocs.io/en/release-1.4/arch-deep-dive.html https://doi.org/10.1007/s11276-018-1883-0 https://cloudsecurityalliance.org/press-releases/2021/06/28/new-cloud-security-alliance-research-evaluates-hyperledger-fabric-2-0-security-provides-guidance-mapped-to-nist-cybersecurity-framework/ https://cloudsecurityalliance.org/press-releases/2021/06/28/new-cloud-security-alliance-research-evaluates-hyperledger-fabric-2-0-security-provides-guidance-mapped-to-nist-cybersecurity-framework/ https://cloudsecurityalliance.org/press-releases/2021/06/28/new-cloud-security-alliance-research-evaluates-hyperledger-fabric-2-0-security-provides-guidance-mapped-to-nist-cybersecurity-framework/ https://cloudsecurityalliance.org/press-releases/2021/06/28/new-cloud-security-alliance-research-evaluates-hyperledger-fabric-2-0-security-provides-guidance-mapped-to-nist-cybersecurity-framework/ http://Who.int https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified http://Psi-inc.org http://Psi-inc.org https://www.psi-inc.org/therapeutic-categories https://www.psi-inc.org/therapeutic-categories http://Businesswire.com https://www.businesswire.com/news/home/20211116005249/en/Four-in-10-Patients-Fear-Pharmaceutical-Supply-Chain-Issues-Pose-Risk-of-Illness-Death https://www.businesswire.com/news/home/20211116005249/en/Four-in-10-Patients-Fear-Pharmaceutical-Supply-Chain-Issues-Pose-Risk-of-Illness-Death https://www.businesswire.com/news/home/20211116005249/en/Four-in-10-Patients-Fear-Pharmaceutical-Supply-Chain-Issues-Pose-Risk-of-Illness-Death https://www.edelman.com/sites/g/files/aatuss191/files/2021-05/Global https://www.edelman.com/sites/g/files/aatuss191/files/2021-05/Global http://Who.int https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products https://doi.org/10.1108/JMTM-03-2019-0118 https://doi.org/10.1108/JMTM-03-2019-0118 https://www.scmp.com/news/hong-kong/law-and-crime/article/3018443/customs-seize-76-boxes-suspected-counterfeit-hpv https://www.scmp.com/news/hong-kong/law-and-crime/article/3018443/customs-seize-76-boxes-suspected-counterfeit-hpv https://www.scmp.com/news/hong-kong/law-and-crime/article/3018443/customs-seize-76-boxes-suspected-counterfeit-hpv https://www.thaipbsworld.com/officials-seize-bt80m-of-fake-botox-stem-cells-and-fillers-in-bangkok/ https://www.thaipbsworld.com/officials-seize-bt80m-of-fake-botox-stem-cells-and-fillers-in-bangkok/ https://www.health.harvard.edu/blog/dermal-fillers-the-good-the-bad-and-the-dangerous-201907152561 https://www.health.harvard.edu/blog/dermal-fillers-the-good-the-bad-and-the-dangerous-201907152561 https://www.health.harvard.edu/blog/dermal-fillers-the-good-the-bad-and-the-dangerous-201907152561 https://apps.who.int/iris/bitstream/handle/10665/64776/WHO_EPI_LHIS_98.02.pdf?sequence=1&isAllowed=y https://apps.who.int/iris/bitstream/handle/10665/64776/WHO_EPI_LHIS_98.02.pdf?sequence=1&isAllowed=y https://apps.who.int/iris/bitstream/handle/10665/64776/WHO_EPI_LHIS_98.02.pdf?sequence=1&isAllowed=y https://cdn2.hubspot.net/hubfs/4107558/general https://cdn2.hubspot.net/hubfs/4107558/general https://www.pharmexec.com/view/e-labeling-change-underway https://www.pharmexec.com/view/e-labeling-change-underway https://doi.org/10.1080/1331677X.2021.1922090 https://www.marketsandmarkets.com/Market-Reports/track-trace-solution-market-158898570.html https://www.marketsandmarkets.com/Market-Reports/track-trace-solution-market-158898570.html https://www.marketsandmarkets.com/Market-Reports/track-trace-solution-market-158898570.html https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region Citation: Blockchain in Healthcare Today 2022, 5: 231 - http://dx.doi.org/10.30953/bhty.v5.23110 Corrine Sim and Haisheng Zhang news-articles/2018/1/the-drug-regulatory-landscape-in-the-ase- an-region [cited 28 April 2022]. 26. McGrail S. Pharmaceutical supply chain cybersecurity risk tops $31M annually [Internet]. Pharmanews Intelligence; 2021. Available from: https://pharmanewsintel.com/news/pharmaceu- tical-supply-chain-cybersecurity-risk-tops-31b-annually [cited 28 April 2022]. 27. Duan Y, Miao M, Wang R, Fu Z, Xu M. A framework for the successful implementation of food traceability systems in China. Inform Soc. 2017;33(4):226–42. https://doi.org/10.1080/0197224 3.2017.1318325 28. Belchior R, Vasconcelos A, Guerreiro S, Correia M. A survey on blockchain interoperability: past, present, and future trends. ACM comput Surv. 2022;54(8):1–41. https://doi. org/10.1145/3471140 29. Belchior RAP. Blockchain interoperability. 2021. Available from: https://web.ist.utl.pt/~ist180970/papers/phd_cat_rafael_ belchior.pdf [cited 28 April 2022]. Copyright Ownership: This is an open access article distributed in ac- cordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, adapt, en- hance this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/ by-nc/4.0. http://dx.doi.org/10.30953/bhty.v5.231 https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region https://pharmanewsintel.com/news/pharmaceutical-supply-chain-cybersecurity-risk-tops-31b-annually https://pharmanewsintel.com/news/pharmaceutical-supply-chain-cybersecurity-risk-tops-31b-annually https://doi.org/10.1080/01972243.2017.1318325 https://doi.org/10.1080/01972243.2017.1318325 https://doi.org/10.1145/3471140 https://doi.org/10.1145/3471140 https://web.ist.utl.pt/~ist180970/papers/phd_cat_rafael_belchior.pdf https://web.ist.utl.pt/~ist180970/papers/phd_cat_rafael_belchior.pdf http://creativecommons.org/licenses/by-nc/4.0 http://creativecommons.org/licenses/by-nc/4.0